The YODA Project
Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2024 – 0428
Date:	April 26, 2024
Product Name:	Remicade/Simponi/Stelara
Therapeutic Area:	Immunology
Product Class:	Antirheumatic Agents – Biologic Response Modifiers
Condition(s) Studied:	Crohn's Disease/Ulcerative Colitis
Protocol Number(s) and Title(s):	1. NCT00553176 - C0168Z01: Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry 2. NCT00036439 - C0168T37: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis 3. NCT00096655 - C0168T46: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis 4. NCT00488631 - C0524T18: A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis 5. NCT00487539 - C0524T17: A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis 6. NCT00488774 - C0524T16 - A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis 7. NCT02407236 - CNTO1275UCO3001 - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis 8. NCT00771667 - C0743T26 - A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy 9. NCT01369342 - CNTO1275CRD3002 - A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of\ Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)

The YODA Project
Research Proposal Due Diligence Assessment

	10. NCT01369355 - CNTO1275CRD3003 - A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease 11. NCT01369329 - CNTO1275CRD3001 - A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)

Part 2: Data Availability

Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	

Part 3: Data Availability Summary

Based on the responses to the above Data Availability questions, the requested clinical trial data are available for a data sharing request.	Yes

Part 4: Proposal Review

Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	